Melatonin protected against myocardial infarction injury in rats through a Sirt6-dependent antioxidant pathway

*Yingcui Wang¹B–D,F, *Suhua Zhang²B,E, Yingying Ma³C,E, Aixia Xiang⁴E, Hui Sun⁴E, Jun Song⁴C, Wenjing Yang¹E, Xuanlong Li¹E, Hongxiao Xu¹A,D,F

¹ Department of Cardiology, Qilu Hospital (Qingdao), Cheeolo College of Medicine, Shandong University, China
² Department of Geriatrics, Qilu Hospital (Qingdao), Cheeolo College of Medicine, Shandong University, China
³ Qingdao Jimo District Center for Disease Control and Prevention, China
⁴ Jimo People’s Hospital, Qingdao, China

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; D – writing the article; E – critical revision of the article; F – final approval of the article

Address for correspondence
Hongxiao Xu
E-mail: xuhongxqlh@163.com

Funding sources
This work was supported by Key Fund of Department of Cardiology, Shandong University Qilu Hospital (Qingdao) (QDR2019MD04), People’s Livelihood Science and Technology Project of Qingdao (application of DEEPVESSEL FFR in coronary artery heart disease complicated with diabetes mellitus), Qingdao Key Health Discipline Development Fund.

Conflict of interest
None declared

Received on August 8, 2018
Reviewed on February 25, 2019
Accepted on September 1, 2019
Published online on January 25, 2022

Abstract

Background. The Sirt6, one of the members of the sirtuin family, has been regarded as a key factor in the pathogenesis of myocardial infarction (MI) through its antioxidant defense mechanisms. A previous study reported that melatonin is an antioxidant drug that can act as an agent for cardioprotection in cardiac ischemia-reperfusion (I/R) injury. However, whether melatonin could protect against cardiac remodeling after myocardial injury via the Sirt6-dependent antioxidant pathway remains unknown.

Objectives. To explore the protective effects and the potential mechanisms of melatonin on MI-induced injury in rats.

Materials and methods. A cardiac remodeling model was established through left coronary artery ligation surgery. The dose of melatonin was 10 mg/kg body weight. Four weeks after the treatment for 7 successive days, the infarct size and hemodynamic parameters were evaluated. The relative mRNA level and protein level of Sirt6 were also determined. Finally, the levels of oxidative stress, including reactive oxygen species (ROS) and superoxide dismutase (SOD), were measured, and the expression of nitric oxide (NO), inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS) and their corresponding phosphorylation were evaluated.

Results. After the treatment with melatonin, infarct size, the left ventricular end-diastolic diameter (LVEDd), and left ventricular end-systolic diameter (LVEDd) and minimum first derivative of developed pressure (min dP/dt) decreased, while left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS) and maximum first derivative of developed pressure (max dP/dt) increased in the melatonin-MI (MM) group compared to the placebo-MI (PM) group. Furthermore, the expressions of Sirt6, both in mRNA and protein level, were significantly increased in the MM group treated with melatonin, as compared to the melatonin-control (MC) group treated with melatonin. In addition, melatonin enhanced SOD activity and reduced ROS levels. At the same time, we observed that the eNOS/NO signaling pathways were activated.

Conclusions. Melatonin improved cardiac function through the Sirt6-dependent antioxidant pathway in MI rats.

Key words: melatonin, oxidative stress, acute myocardial infarction, sirtuin

Cite as
Wang Y, Zhang S, Ma Y, et al. Melatonin protected against myocardial infarction injury in rats through a Sirt6-dependent antioxidant pathway. Adv Clin Exp Med. 2022;31(3):277–284. doi:10.17219/acem/112060

DOI
10.17219/acem/112060

Copyright
Copyright by Author(s)
This is an article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) (https://creativecommons.org/licenses/by/3.0/)
Background

Acute myocardial infarction (MI) is generally caused by coronary artery disease (CAD), which remains a leading cause of morbidity and mortality and imposes a tremendous economic burden worldwide.1 After MI injury, the heart undergoes a series of cardiac wound-healing responses, including cardiomyocyte necrosis and apoptosis, inflammation, and cardiac hypertrophy and fibrosis. As cardiac wound healing progresses, patients suffer from post-MI left ventricular (LV) remodeling, heart failure (HF) or even death.2,3

Oxidative stress plays an important role in the pathophysiology of various cardiovascular disorders, including atherosclerosis, cardiac hypertrophy, cardiomyopathy, HF, ventricular remodeling, and myocardial injury after ischemia followed by reperfusion (I/R). During the development of cardiac remodeling, oxidative stress aggravates heart disease into HF.4–6 Elevated oxidative stress may result in peroxidation of proteins, DNA and lipids, triggering mitochondria-induced cell death pathways and contributing to I/R injury.7

The Sirt6 is one of the 7 mammalian sirtuin homologs and it contains a domain with NAD+ -dependent deacetylase activity.8 Among sirtuin family members, both Sirt1 and Sirt6 have demonstrated cardioprotective abilities. However, no direct evidence can verify the antioxidantive role of Sirt1 in protecting heart function, while Sirt6 has been shown to play a vital protective role in cardiomyocytes in I/R through its antioxidative ability.9

Melatonin, a hormone synthesized and secreted by the pineal gland, is a well-known antioxidant.10,11 Extensive evidence suggests that melatonin has profound cardioprotective effects.12,13 For example, Hu et al. demonstrated that melatonin alleviated post-infarction cardiac remodeling and dysfunction by inhibiting Mst1.14 Zhou et al. demonstrated that melatonin protected against I/R in myocardial infarction by suppressing platelet activation and function.15 However, whether melatonin could protect against cardiac remodeling after myocardial injury via a Sirt6-dependent antioxidant pathway, remains unknown.

Objectives

The aim of the study was to explore the protective effects and the potential mechanisms of melatonin on MI-induced injury in rats.

Materials and methods

The animals

All the experiments were performed with the approval of the Ethics Committee at Shandong University Qilu Hospital (approval No. KYLL-KS-2021180). Three-month-old male Wistar rats weighing 250–270 g were purchased from Charles River Laboratories (Beijing, China). The rats were randomly divided into 4 groups: placebo-control (PC), melatonin-control (MC), placebo-MI (PM), and melatonin-MI (MM). Each group included 10 rats. In the PM and MM groups, the rat MI model was established through left coronary artery ligation surgery. In addition, the PC group was regarded as a negative control group, and it was designed to show whether the model was established successfully and to eliminate the influence of the operation.

Rat MI model

The rats were placed in an induction chamber and 4% isoflurane was delivered until they reached a deep plane of anesthesia. After the intubation was finished, the chest was opened at the left 4th intercostal space. The pericardial tissue was removed and the left anterior descending artery was visualized under a light microscope (model YAN-6A; Yuyan Instruments Co., Ltd., Shanghai, China) and ligated by a 6-0 silk suture (Yuyan Instruments), 1 mm below the tip of the left atrial appendage. The PC and MC groups underwent surgery without the left anterior descending artery ligation. After ligation, the left artery presented a pale appearance. Echocardiography was used to confirm the successful ligation, which would appear as ST segment and Q wave changes.

Melatonin treatment

For 7 days following the surgical procedures, melatonin (Sigma-Aldrich, St. Louis, USA) dissolved in dimethyl sulfoxide was administered to the MC and MM groups by daily intraperitoneal injection, at a dose of 10 mg/kg body weight. In the placebo groups, an equivalent volume of dimethyl sulfoxide (DMSO) was injected.

Hemodynamic measurement and determination of infarct size

A microtip catheter transducer (Millar Instruments, Houston, USA) was inserted into the right carotid artery and advanced into the left ventricle to measure the following parameters: the left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVESd), left ventricular ejection fraction (LVEF) and fractional shortening (FS). For the hemodynamic analysis, LV maximum first derivative of developed pressure (max dP/dt), and LV minimum first derivative of developed pressure (min dP/dt) were analyzed. Four weeks after the treatment, the animals were anesthetized again for hemodynamic measurement as described in another study.16

Infarct size was determined with Masson’s trichrome staining as described in an earlier publication.17 After the animals were sacrificed, the LV myocardium was dissected,
fixed in 4% paraformaldehyde, embedded in paraffin, and then cut into 7-μm sections. The sections were stained with Accustain Trichrome Stain (Masson) kit (Sigma-Aldrich).

Infarct size was determined using the Microsoft Image Composite Editor v. 14.4 (Microsoft Corp., Redmond, USA).

**Measurement of Sirt6 in mRNA and protein levels**

The primary rat cardiomyocytes were isolated and cultured from the animals in the 4 groups as described in a previous study. When the cells were prepared, the expression of Sirt6 in cardiomyocytes was measured using western blot and quantitative real-time polymerase chain reaction (qRT-PCR). The anti-Sirt6 (Cell Signaling Technology, Danvers, USA) and tubulin (T5168; Sigma-Aldrich) were used. The following primers were used: Sirt6: forward 5′-TCTTCCAGTGTGGTTCCA, reverse 5′-CTCCATGGTCCAGACTCC; β-actin: forward 5′-CCAACCGCGAGAAGATGA, reverse 5′-CCAGAGGCGTACAGGGATAG.

**Analysis of oxidative stress (ROS and SOD)**

Intracellular reactive oxygen species (ROS) production in cardiomyocytes was evaluated with a fluorometric assay using 2',7'-dichlorofluorescein diacetate (DCFH-DA; Molecular Probes, Eugene, USA), according to the manufacturer’s protocols. The cells were incubated with DCFH-DA for 1 h, after which the fluorescence intensity was measured at 488 nm and 525 nm emission wavelengths. Lysate and cardiomyocytes from fresh rat hearts were collected before total superoxide dismutase (SOD) activity was determined, using a commercial SOD Kit (Beyotime Biotech Inc., Jiangsu, China). The 50% inhibition activity of SOD (IC50) values was determined under an optic density (OD) of 560 nm, using a Model 550 Microplate Reader (Bio-Rad Laboratories Inc., Hercules, USA).

**Nitric oxide measurement**

The level of nitric oxide (NO) in MI cardiac tissue was detected using a diagnostic assay kit (Nanjing Jiancheng Bioengineering Research Institute, Nanjing, China) as described in a previous study.

**Measurement of iNOS and eNOS with western blot**

Total proteins were extracted from LV tissues. Protein concentrations were detected using a Pierce BCA Assay Kit (Thermo Fisher Scientific Inc., Waltham, USA). Then, samples containing 20 μg protein were resolved with electrophoresis on 10% polyacrylamide gels and transferred to polyvinylidene fluoride (PVDF) membranes. Rabbit anti-endothelial nitric oxide synthase (eNOS), anti-inducible nitric oxide synthase (iNOS), polyclonal antibodies, rabbit anti-P1177 eNOS, and rabbit anti-GAPDH monoclonal antibody (all from Abcam, Cambridge, USA) were used to detect the levels of iNOS, eNOS and phosphorylated eNOS (p-eNOS) in this assay.

**Statistical analyses**

Data were shown as median and interquartile range (IQR) due to a small sample size. Statistically significant differences among the groups were analyzed using the Kruskal–Wallis test. Pairwise multiple comparisons post hoc tests were carried out using Dunn’s test with a Bonferroni correction. Two-tailed, unpaired Mann–Whitney tests were used to analyze the comparisons between 2 groups. The value of p < 0.05 was taken to indicate statistical significance.

**Results**

**Melatonin decreased the myocardial infarct size in the rat MI model**

As shown in Fig. 1A, in which the fibrotic scar appears blue and the viable myocardium is red, melatonin did not affect the cardiac structure in the MC group, while in the MM group, melatonin treatment decreased the myocardial infarct size (U = 0; p < 0.0001). The quantitative analysis confirmed this finding (Fig. 1B).

**Melatonin improved hemodynamic parameters**

Hemodynamic analyses were performed in all 4 groups. In the MM group, LVEDd, LVESd and min dP/dt decreased, while LVEF, LVFS and max dP/dt increased, but there was no significant difference after Dunn’s Bonferroni adjustment (Table 1). No differences in these parameters were observed in the MC group, as shown in Fig. 2.

**Melatonin increased Sirt6 expression both in mRNA and protein levels**

After treatment with melatonin, the expressions of Sirt6 both in mRNA (p < 0.0001 after adjustment) and protein levels (p < 0.0001 after adjustment) were increased in the MM group compared to the PM group, as shown in Fig. 3 (Table 1).

**Melatonin ameliorated MI-induced oxidative stress**

Because of the fact that increased oxidative stress deteriorated cardiac remodeling, 2 oxidative stress-related...
molecules were detected. The results indicated that when treated with melatonin, the ROS level from primary cardiomyocytes was lowered in the MM group compared to the PM group, yet it was nonsignificant after Dunn’s Bonferroni adjustment (p = 0.3343; Table 1). There was no significant difference among the PC and MC groups, as shown in Fig. 4A. The SOD activity was enhanced in the MM group compared to the PM group, but it was nonsignificant after Dunn’s Bonferroni adjustment (p = 0.3336; Table 1), as shown in Fig. 4B.

Table 1. The comparisons between multiple groups after Kruskal–Wallis test and the comparisons between the melatonin-treated myocardial infarction group (MM) and the placebo-treated myocardial infarction group (PM) after Bonferroni adjustment

| Outcomes                  | Kruskal–Wallis χ² test | df | p-value among groups | Comparisons                  | Bonferroni-adjusted p-value |
|---------------------------|------------------------|----|----------------------|-------------------------------|-----------------------------|
| LVEDd [%]                 | 35.08                  | 3  | <0.0001              | MM vs. PM                    | 0.3339                      |
| LVEF [%]                  | 32.95                  | 3  | <0.0001              | MM vs. PM                    | 0.3345                      |
| Max dP/dt [mm Hg/s]       | 32.93                  | 3  | <0.0001              | MM vs. PM                    | 0.3347                      |
| LVESd [%]                 | 33.02                  | 3  | <0.0001              | MM vs. PM                    | 0.3345                      |
| LVFS [%]                  | 34.23                  | 3  | <0.0001              | MM vs. PM                    | 0.3341                      |
| Min dP/dt [mm Hg/s]       | 32.98                  | 3  | <0.0001              | MM vs. PM                    | 0.3347                      |
| Sirt6 mRNA expression     | 32.94                  | 3  | <0.0001              | MM vs. PM                    | <0.0001                     |
| Sirt6 protein expression  | 30.29                  | 3  | <0.0001              | MM vs. PM                    | <0.0001                     |
| ROS (fold)               | 33.01                  | 3  | <0.0001              | MM vs. PM                    | 0.3343                      |
| SOD (fold)               | 33.01                  | 3  | <0.0001              | MM vs. PM                    | 0.3336                      |
| NO relative level        | 32.99                  | 3  | <0.0001              | MM vs. PM                    | 0.3346                      |
| eNOS protein/actin       | 32.97                  | 3  | <0.0001              | MM vs. PM                    | <0.0001                     |
| p-eNOS protein/actin     | 33.17                  | 3  | <0.0001              | MM vs. PM                    | 0.3343                      |
| iNOS protein/actin       | 21.98                  | 3  | <0.0001              | MM vs. PM                    | 0.0008                      |
| p-iNOS protein/actin     | 24.24                  | 3  | <0.0001              | MM vs. PM                    | 0.0136                      |

LVEDd – left ventricular end-diastolic diameter; LVEF – left ventricle ejection fraction; max dP/dt – maximum first derivative of developed pressure; LVESd – left ventricular end-systolic diameter; LVFS – left ventricular fractional shortening; Min dP/dt – minimum first derivative of developed pressure; ROS – reactive oxygen species; SOD – superoxide dismutase; NO – nitric oxide; eNOS – endothelial nitric oxide synthase; p-eNOS – phosphorylated eNOS; iNOS – inducible nitric oxide synthase; p-iNOS – phosphorylated iNOS; df – degrees of freedom.
Melatonin increased eNOS and NO production and inhibited iNOS production

In order to demonstrate whether the important role of melatonin as an antioxidant was involved in NO signaling, we performed assays to measure the production of NO-related molecules. The results showed that the levels of NO (p = 0.3346 after adjustment when compared to the PM group), eNOS (p < 0.0001 after adjustment) and p-eNOS (p = 0.3343 after adjustment when compared to the PM group) were increased in the MM group, but not in the PC and MC group, as shown in Fig. 5. This indicated that melatonin might promote cardioprotection by activating the eNOS/NO signaling pathway. At the same time, we found that the levels of iNOS (p = 0.0008 after adjustment when compared to the PM group) and phosphorylated iNOS (p-iNOS) (p = 0.0136 after adjustment when compared to the PM group) were significantly decreased when treated with melatonin in the hearts of the MM rats but not in the PC and MC groups, as shown in Fig. 5C. This indicated that melatonin might promote cardioprotection by inhibiting iNOS (Table 1).
Discussion

Melatonin can counteract many pathological conditions, such as cardiovascular disorders, carcinogenesis, neurological diseases, and aging.19 Recently, its cardioprotective function has gained a great deal of attention.20–23 More and more evidence suggests that the cardioprotective functions of melatonin are due to its direct free radical scavenger properties, antioxidant activities and anti-inflammatory effects. In this study, we confirmed the cardioprotective role of melatonin in an animal model of MI, and for the first time we found that melatonin improved cardiac remodeling through a Sirt6-dependent antioxidant pathway.
Pharmacological data have clearly demonstrated the powerful antioxidant properties of melatonin. For example, melatonin can protect the brain as a potent antioxidant, anti-inflammatory and anti-apoptotic agent. Melatonin has been shown to prevent granulosa cells from oxidative damage by targeting JNK-mediated autophagy, which may hold promise for patients with ovulation failure-related disorders.

In order to investigate the cardioprotective role of melatonin on MI, we established a MI rat model by ligating the left anterior descending coronary artery and verifying ST elevation using electrocardiography (ECG). Four weeks after the treatment with melatonin, infarct size and hemodynamic parameters were measured. Infarct size was reduced significantly after the treatment with melatonin, which indicated that melatonin could protect the infarcted myocardium. Similarly, the results of hemodynamic studies indicated that post-MI cardiac remodeling had improved significantly following the treatment with melatonin.

Accumulated evidence indicates that oxidative stress is responsible for the progression of cardiac remodeling. In order to investigate whether the cardioprotective effect of melatonin functions through its antioxidant role, ROS and SOD levels were measured as the indicators of oxidative stress. Excessive ROS accumulation leads to cellular oxidative stress and elicits an increased pro-inflammatory response, which is associated with cardiac remodeling. Not surprisingly, after the treatment with melatonin, we found that ROS activity reduced significantly and SOD level increased significantly in the MM group. The evidence suggested that melatonin could prevent cardiac remodeling by decreasing oxidative stress.

The NO is a widely known ventricular dilator produced from L-arginine by a family of NOS, including eNOS and iNOS. It has been shown that NO plays a role in reducing oxidative stress and elicits an increased pro-inflammatory response, which is associated with cardiac remodeling. Not surprisingly, after the treatment with melatonin, we found that ROS activity reduced significantly and SOD level increased significantly in the MM group. In our study, the expressions of NO, iNOS, eNOS, and their corresponding phosphorylations were determined. The results indicated that the expressions of NO and eNOS were upregulated and the expression of iNOS was lowered in the MM group compared to the PM group. This evidence suggests that melatonin might suppress the processes of oxidative stress by activating the eNOS/NO signaling pathway and inhibiting iNOS signaling pathway.

Interestingly, we found that the expressions of Sirt6, both in mRNA and protein levels, were significantly increased in the MM group compared to the PM group. This indicates that Sirt6 might be the target through which melatonin improves oxidative stress by activating the eNOS/NO signaling pathway in the heart.

In spite of the fact that a dose of 10 mg/kg of melatonin administered via intraperitoneal injection works cardioprotectively in the MM group, there is still no evidence to demonstrate whether this dose works for humans. Actually, it was reported that a total dose of 50 mg has been used during a major vascular surgery. Regrettfully, those researchers concluded that intracoronary and intravenous administration of melatonin did not improve the myocardial salvage index in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. Hopefully, if the dose of melatonin was increased to 10 mg/kg, it would demonstrate some beneficial effects for the heart, considering its obvious Sirt6-dependent antioxidative ability in I/R. However, this speculation still needs to be verified.

Limitations

Firstly, this study proved the effect of melatonin on mouse MI model, but there is still no evidence to demonstrate whether this works for humans. Secondly, the study had no designed not designed dose gradient, so the optimal dose of melatonin for MI could not be obtained. Thirdly, we only analyzed the changes of Sirt6 expression and did not verify whether the knockout of Sirt6 would eliminate the cardioprotective effect of melatonin.

Conclusions

The current study demonstrated for the first time that intraperitoneal injection of melatonin could improve the cardiac function via a Sirt6-dependent antioxidant pathway in MI rats.

ORCID iDs

Yingcui Wang https://orcid.org/0000-0002-7982-5587
Suhua Zhang https://orcid.org/0000-0002-6754-5457
Aixia Xiang https://orcid.org/0000-0001-7790-9982
Hui Sun https://orcid.org/0000-0003-3941-860X
Jun Song https://orcid.org/0000-0003-1456-2234
Wenjing Yang https://orcid.org/0000-0002-6981-5019
Xuanlong Li https://orcid.org/0000-0001-5763-6702
Hongxiao Xu https://orcid.org/0000-0002-1119-3050

References

1. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017;389(10065):197–210. doi:10.1016/S0140-6736(16)30677-8
2. Li F, Zong J, Zhang H, et al. Orientin reduces myocardial infarction size via eNOS/NO signaling and thus mitigates adverse cardiac remodeling. Front Pharmacol. 2017;8:926. doi:10.3389/fphar.2017.00926
3. Wang Y, Wang Q, Yu W, Du H. Crocin attenuates oxidative stress and myocardial infarction injury in rats. Int Heart J. 2018;59(2):387–393. doi:10.1536/ihj.17-114
4. Sinning C, Westermann D, Clemmensen P. Oxidative stress in ischemia and reperfusion: Current concepts, novel ideas and future perspectives. BioMed. 2017;11(1):11031–11040. doi:10.2217/bmm-2017-0110
5. Jain AK, Mehra NK, Swarnakar NK. Role of antioxidants for the treatment of cardiovascular diseases: Challenges and opportunities. Curr Pharm Des. 2015;21(30):4441–4455. doi:10.2174/138161282166150803151758
6. Yang Y, Li F, Zhang H, et al. Guanxin działa z gradaczą na krążowy mięsień przy ograniczaniu stresu. Evid Based Complement Alternat Med. 2017;2017:4534387. doi:10.1155/2017/4534387
7. Zhou T, Prather ER, Garrison DE, Zuo L. Interplay between ROS and antioxidants during ischemia-reperfusion injuries in cardiac and skeletal muscle. Int J Mol Sci. 2018;19(2):417. doi:10.3390/ijms19020417
8. Pan H, Guan D, Liu X, et al. SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2. Cell Res. 2016;26(2):190–205. doi:10.1038/cr.2016.4

9. Wang XX, Wang XL, Tong MM, et al. SIRT6 protects cardiomyocytes against ischemia/reperfusion injury by augmenting FoxO3a-dependent antioxidant defense mechanisms. Basic Res Cardiol. 2016;111(2):13. doi:10.1007/s00395-016-0531-z

10. Yang HL, Zhou WJ, Gu CJ, et al. Pleiotropic roles of melatonin in endometriosis, recurrent spontaneous abortion, and polycystic ovary syndrome. Am J Reprod Immunol. 2018;80(1):e12839. doi:10.1111/aji.12839

11. Taniguti EH, Ferreira YS, Stupp UV, et al. Neuroprotective effect of melatonin against lipopolysaccharide-induced depressive-like behavior in mice. Physiol Behav. 2018;188:270–275. doi:10.1016/j.physbeh.2018.02.034

12. Zhou H, Ma Q, Zhu P, Ren J, Reiter RJ, Chen Y. Protective role of melatonin in cardiac ischemia-reperfusion injury: From pathogenesis to targeted therapy. J Pineal Res. 2018;64(3). doi:10.1111/jpi.12471

13. Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: Protective effects of melatonin. J Pineal Res. 2008;44(1):16–25. doi:10.1111/j.1600-079X.2007.00518.x

14. Hu J, Zhang L, Yang Y, et al. Melatonin alleviates post-infarction cardiac remodeling and dysfunction by inhibiting Mst1. J Pineal Res. 2017;62(1). doi:10.1111/jpi.12368

15. Zhou H, Li D, Zhu P, et al. Melatonin suppresses platelet activation and function against cardiac ischemia/reperfusion injury via PPARgamma/FUNDC1/mitophagy pathways. J Pineal Res. 2017;63(4). doi:10.1111/jpi.12438

16. Faria TO, Simoes MR, Vassallo OV, et al. Xanthine oxidase activation modulates the endothelial (vascular) dysfunction related to HgCl2 exposure plus myocardial infarction in rats. Cardiovasc Toxicol. 2018;18(2):161–174. doi:10.1007/s12012-017-9427-x

17. Gao L, Kupfer ME, Jung JP, et al. Myocardial tissue engineering with cells derived from human-induced pluripotent stem cells and a native-like, high-resolution, 3-dimensionally printed scaffold. Circ Res. 2017;120(8):1318–1325. doi:10.1161/CIRCRESAHA.116.310277

18. Cao J, Xie H, Sun Y, et al. Sevoflurane post-conditioning reduces rat myocardial ischemia reperfusion injury through an increase in NOS and a decrease in phosphorylated NHE1 levels. Int J Mol Sci. 2015;16(6):1529–1537. doi:10.3390/ijms.15206

19. Favero G, Franceschetti L, Buffoli B, et al. Melatonin: Protection against age-related cardiac pathology. Ageing Res Rev. 2017;35:336–349. doi:10.1016/j.arr.2016.11.007

20. Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: Under promises but over delivers. J Pineal Res. 2016;61(3):253–278. doi:10.1111/jpi.12360

21. Reiter RJ, Tan DX, Paredes SD, Fuentes-Broto L. Beneficial effects of melatonin on myocardial disease. Ann Med. 2010;42(4):276–285. doi:10.3109/07853890903485748

22. Ekloef S, Halladin N, Fonnés S, et al. Effect of intracoronary and intravenous melatonin on myocardial salvage index in patients with STElevation myocardial infarction: A randomized placebo controlled trial. J Cardiovasc Transl Res. 2017;10(5–6):470–479. doi:10.1007/s12265-017-9768-7

23. Domínguez-Rodríguez A, Abreu-González P, Reiter RJ. Melatonin as an agent for cardioprotection in patients with ST-elevation myocardial infarction and short ischaemic time. Cardiovasc Drugs Ther. 2017;31(2):227–228. doi:10.1007/s10557-016-6708-8

24. Lin X, Zhao T, Lin CH, et al. Melatonin provides protection against heat stroke-induced myocardial injury in male rats. J Pharm Pharmacol. 2018;70(6):760–767. doi:10.1111/jphp.12895

25. Debnath B, Hussain M, Irshad M, et al. Exogenous melatonin mitigates acid rain stress to tomato plants through modulation of leaf ultrastructure, photosynthesis and antioxidant potential. Molecules. 2018;23(2):388. doi:10.3390/molecules23020388

26. Kratz EM, Piwowar A. Melatonin, advanced oxidation protein products and total antioxidant capacity as seminal parameters of antioxidant–antioxidant balance and their connection with expression of metalloproteinases in context of male fertility. J Physiol Pharmacol. 2017;68(5):659–668. PMID:29375040.

27. Aridas JDS, Yawno T, Sutherland AE, et al. Systemic and transferable melatonin administration prevents neuropathology in response to perinatal asphyxia in newborn lambs. J Pineal Res. 2018;64(4):e12479. doi:10.1111/jpi.12479

28. Cao Y, Shen M, Jiang Y, Sun SC, Liu H, Melatonin reduces oxidative damage in mouse granulosa cells via restraining JNK-dependent autophagy. Reproduction. 2018;155(3):307–319. doi:10.1530/REP-18-0002

29. Ayoub KF, Pothineni NVK, Rutland J, Ding Z, Mehta JL. Immunity, inflammation, and oxidative stress in heart failure: Emerging molecular targets. Cardiovasc Drugs Ther. 2017;31(5–6):593–608. doi:10.1007/s10557-017-6752-z

30. Wu QQ, Xiao Y, Yuan Y, et al. Mechanisms contributing to cardiac remodelling. Clin Sci (Lond). 2017;131(18):2319–2345. doi:10.1042/CS20171167

31. Diudla PV, Joubert E, Muller CJF, Louw J, Johnson R. Hyperglycaemia-induced oxidative stress and heart disease-cardioprotective effects of rooibos flavonoids and phenylpyruvic acid-2-O-beta-D-glucoside. J Physiol Pharmacol. 2017;68(2):381–395. doi:10.1016/j.jphysparis.2016.10.006

32. Jin S, Teng X, Xiao L, et al. Hydrogen sulfide ameliorated L-NAME-induced hypertensive heart disease by the Akt/eNOS/NO pathway. Exp Biol Med (Maywood). 2017;242(18):1831–1841. doi:10.1177/1537370117732325

33. Zhang YH, Casadei B. Sub-cellular targeting of constitutive NOS in health and disease. J Mol Cell Cardiol. 2012;52(2):341–350. doi:10.1016/j.yjmcc.2011.09.006

34. Hu J, Zhang YX, Wang L, et al. Protective effects of Xinji’erkang on myocardial infarction induced cardiac injury in mice. BMC Complement Altern Med. 2017;17(1):338. doi:10.1186/s12906-017-1846-5

35. Ekloef S, Halladin N, Fonnés S, et al. Effect of intracoronary and intravenous melatonin on myocardial salvage index in patients with STElevation myocardial infarction: A randomized placebo controlled trial. J Cardiovasc Transl Res. 2017;10(5–6):470–479. doi:10.1007/s12265-017-9768-7